|
Neonatal Intensive Care Drug Manual
|
| bet | 622/654 | | Sana | 03.01.2022 | | Hajmi | 1,5 Mb. | | #14803 |
Vancomycin-Intermittent
Revision Date : 16-11-2020
|
Approved: TC, KOH
|
Alert
|
S4 - High risk medicine
Antimicrobial Stewardship Team recommends this drug is listed as: Restricted.
Continuous infusion regimen optimises achievement of steady state target concentration with fewer dose adjustments and a lower total daily dose in comparison to intermittent regimen.
|
Indication
|
Infections due to susceptible strains of Staphylococci (including MRSA), Streptococci, Enterococci, Diptheroids, Listeria monocytogenes, Actinomyces, Bacillus sp
|
Action
|
Bactericidal agent which interferes with cell wall synthesis, inhibits RNA synthesis and alters plasma membrane function.
|
Drug type
|
Glycopeptide antibiotic.
|
Trade name
|
DBL Vancomycin Hydrochloride, Vancocin CP, Vancomycin Alphapharm, Vancomycin AN powder for infusion. Vancomycin Sandoz Vycin
|
Presentation
|
Vancomycin hydrochloride 500 mg vial
Vancomycin hydrochloride 1000 mg vial
|
Dose
|
|
|
| |
